Elite Pharmaceuticals Inc (ELTP)

[Couch]

TO THE NEWBIES INTERESTED IN BUYING THIS STOCK:

(I'll provide a few more DD links below for those wanting some additional reading)

What I would first say is what you should already know by heart - Do your own DD and don't spend what you can't afford to lose. Beyond that this is the OTC and 9/10 you either make a killing or you go broke: Regarding ELTP - IMO you will make a killing here.

On a brief side note I started investing in ELTP in March of 2011. Just look at how far the company has come since then. I've never worried about the company making it even when they were months away from BK. I kept buying and buying and buying. High risk High reward. WIN or GO HOME. So look at all the company has accomplished since 2011. IMO there is no better time to invest in the company on the RISK end of the spectrum. IMO .20 cents gets you a $1 minimum upon Eli 200 release.

Take a look:
http://ir.elitepharma.com/press_releases

What I would also point out is the negative hype and how it has changed since 2011: It started out as the following.

1) Elite would go broke and BK before it launched its first generic approval post Lodrane removal in 2011.

2) Elite's abuse deterrent technology (ADT) was second rate and stolen from Purdue and the USPTO would never give Elite a patent. Elite now has 4 US patents and 2 Canadian patents and counting in relation to its propretiary ADT.

3) Elite would never be able to secure adequate financial backing to pay for a Full Phase 3 trial. This one makes me truly laugh out loud. Total BS back then and now.

4) Elite management was second tier and would never amount to anything beyond the minors. Hiring Nasrat Hakim and Doug Plascche has put this argument to rest.

5) Elite would never be able to become Cash Flow Positive off of operations let alone in relation to its R&D costs as well. Guess that Epic $15 million has stopped this talk in its tracks as well.

6) Elite would dilute the stock beyond recognition and thus become a stinky pinky. Total misinformation: Sure the share count has climbed way above what I am comfortable with. STILL, since Nasrat has become CEO ANY INCREASE IN SHARES HAS BEEN OUTSTRIPPED BY AN IMPROVEMENT IN PPS.

SO WHAT DO WE HAVE LEFT regarding "Negative Talking" Points???

NOTICE what we have left. It's not whether the science works, or the quality of management, or access to financial funds.....IT'S HOW MUCH $$$$$$ is Eli 200 going to GARNER.

MAN IF THAT'S what i have to worry about....I'll take that any day of the WEAK over what was present in 2011.

IMO there is no safer bet in the Pharma space right now regarding RISK/REWARD. You spend $1 and upon Eli 200 launch IMO again, you get a minimum of 5 times your ROI. And that is for starters. Elite has another 10 ADT opioids in various stages with ONLY Eli 200 partnered.

http://www.elitepharma.com/pipeline-branded/
http://www.elitepharma.com/pipeline-generics/

Elite has an amazing CEO in Nasrat Hakim. He is the #1 REASON Elite will be recognized as a leader in the abuse deterrent opioid space for many years to come.
Quote:
NASRAT HAKIM President & Chief Executive Officer
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.


1) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114450957

2) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114527754

3) http://www.drug-dev.com/Main/Back-Issues/ROUNDTABLE-DISCUSSION-Reformulating-Opioids-to-Det-648.aspx

4) http://seekingalpha.com/user/4199131/instablog

5) http://seekingalpha.com/article/3429196-elite-pharmaceuticals-eltp-ceo-nasrat-hakim-on-q1-2016-results-earnings-call-transcript

6) http://seekingalpha.com/article/2859876-elite-pharmaceuticals-is-well-positioned-to-address-7b-abuse-deterrent-opioid-market